Prenetics Global (NASDAQ:PRE - Get Free Report) posted its earnings results on Thursday. The company reported ($0.80) earnings per share (EPS) for the quarter, Zacks reports. Prenetics Global had a negative net margin of 191.73% and a negative return on equity of 16.45%. Prenetics Global updated its FY 2025 guidance to EPS and its Q2 2025 guidance to EPS.
Prenetics Global Price Performance
Shares of NASDAQ PRE traded up $0.42 during mid-day trading on Thursday, reaching $8.02. 83,256 shares of the company traded hands, compared to its average volume of 18,816. The firm has a market cap of $97.88 million, a PE ratio of -2.01 and a beta of 0.17. Prenetics Global has a fifty-two week low of $3.09 and a fifty-two week high of $11.99. The stock has a fifty day simple moving average of $6.26 and a 200-day simple moving average of $5.49.
Prenetics Global Company Profile
(
Get Free Report)
Prenetics Global Limited, a genomics-driven health sciences company, engages in revolutionizing prevention, early detection, and treatment. It offers CircleDNA, a prevention arm that uses whole exome sequencing to offer comprehensive consumer DNA test. The company also, through its joint venture, Insighta, engages in pioneering multi-cancer early detection technologies.
See Also
Before you consider Prenetics Global, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Prenetics Global wasn't on the list.
While Prenetics Global currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
